Amarin Corp Plc (AMRN)

[Pharmacydude]

Rose
In the summer of 2021 I had a 1 on 1 video call with Dr Bhatt. We talked about my EPA for COVID paper in which I hypothesized that it was the substrate ratios of EPA and AA at the COX and LOX enzymes that drove the inflammatory response and damage to the body. I pointed out that he had all the EPA and AA data from R-IT and asked if they had looked at the ratios and the effects on outcomes. His response: “there is no plan to do such an analysis at this time”. If Bhatt didn’t think the EPA:AA ratio was important at that time I assure you Amarin could not have marketed it to physicians or Pts that way at the time. Can’t blame JT or KM, it was Bhatt that didn’t act. BP would have been the same.

A few months later I asked the same question to Bhatt’s former boss and mentor Dr Peter Libby. I was able to record that question and you can see from Dr Libby’s response that it was only an unproven theory at the time.

https://drive.google.com/file/d/1xi1vrPEUOukORL2BCoExg_g9mqjPP-Nc/view?usp=drivesdk

Also, if the marketing angle would have been “the EPA:AA ratio is the cause” then any DS would have been seen as a less expensive alternative to bumping up your EPA level.

Focus on the good points: if it’s the EPA:AA ratio controlling inflammation that caused the benefits in R-IT then it further supports the hypothesis that V will be beneficial in several conditions that are driven by systemic inflammation (Alzheimer’s for example)